Top Story

Ramucirumab plus FOLFIRI improved OS in metastatic colorectal cancer

September 15, 2014

Ramucirumab plus FOLFIRI in combination with chemotherapy improved overall survival in metastatic colorectal cancer patients after progression on a bevacizumab-based regimen, according to phase 3 trial results reported recently by Eli Lilly.

“Patients with metastatic colorectal cancer — particularly those in the second-line setting — continue to need new treatment options that improve survival,” Richard Gaynor, MD, senior vice president, product development and medical affairs for Lilly Oncology, said in a press release. “We are pleased that the RAISE study demonstrated a survival benefit and are hopeful that ramucirumab will become a new antiangiogenic treatment option after first-line bevacizumab-containing therapy for metastatic colorectal cancer patients.”

figure

VT-122, sorafenib improved OS in patients with HCC

September 12, 2014
Patients with advanced hepatocellular carcinoma had an increased overall survival rate after treatment with a novel combination of etodolac and propranolol plus…

Continuous imaging system tracked radiation delivery in liver cancer patient

September 11, 2014
A patient with liver cancer at the University of Wisconsin Carbone Cancer Center recently received novel MRI-guided radiation therapy, marking the first time the…
figure In the Journals

Prediabetes increases risks for cancers overall by up to 15%

September 8, 2014
Presence of prediabetes at baseline is associated with a 15% increased risk of cancer overall and when adjusting for BMI, 
CME
figure

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

figure

Ramucirumab plus FOLFIRI improved OS in metastatic colorectal cancer

September 15, 2014
Ramucirumab plus FOLFIRI in combination with chemotherapy improved overall survival in metastatic colorectal cancer patients after progression on a…
figure

VT-122, sorafenib improved OS in patients with HCC

September 12, 2014
Patients with advanced hepatocellular carcinoma had an increased overall survival rate after treatment with a novel combination of etodolac and…

Continuous imaging system tracked radiation delivery in liver cancer patient

September 11, 2014
A patient with liver cancer at the University of Wisconsin Carbone Cancer Center recently received novel MRI-guided radiation therapy, marking the…
figure In the Journals

Prediabetes increases risks for cancers overall by up to 15%

September 8, 2014
Presence of prediabetes at baseline is associated with a 15% increased risk of cancer overall and when adjusting for BMI, 
Industry News

WHO recommends generic name for liver cancer drug candidate

September 5, 2014
WHO’s International Nonproprietary Name group has recommended the generic name mipsagargin for GenSpera’s G-202 in the treatment of…
figure In the Journals

Higher Medicaid reimbursement linked to increased cancer screening rates

September 4, 2014
State-specific increased Medicaid reimbursement for office visits was significantly associated with a greater likelihood for breast, cervical and…
FDA News

FDA grants fast track designation to PEGPH20 program for metastatic pancreatic cancer

September 3, 2014
The FDA granted fast track designation today to Halozyme Therapeutics for its PEGPH20 program in treating patients with pancreatic cancer, according…
Industry News

Concordia partners with Orphan Canada to supply rare cancer drug

September 3, 2014
Pinnacle Biologics, a subsidiary of Concordia Healthcare, has entered into an agreement with Orphan Canada to support the continued supply of…
Industry News

Enrollment starts in OPTIMA global study of ThermoDox as HCC therapy

September 2, 2014
The first patient enrolled in the OPTIMA study for primary liver cancer will be studied at the Kyungpook National University Hospital in South Korea…
In the Journals

LT patients with cirrhosis had increased risk for colorectal neoplasia

September 2, 2014
Patients with viral or alcohol-related cirrhosis awaiting liver transplantation and who underwent colonoscopy were at high risk for developing…
More Headlines »